Mechanisms of Clozapine-Induced Agranulocytosis

Drug Safety

Volumn 7, Issue 1, 1992, Pages 17-25

  Gerson, Stanton L ^a,b   Meltzer, Herbert ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

AGRANULOCYTOSIS; DRUG COMBINATION; DRUG EFFECT; HEMATOPOIESIS; HUMAN; IATROGENIC DISEASE; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

AGRANULOCYTOSIS; CLOZAPINE; DRUG THERAPY, COMBINATION; HEMATOPOIESIS; HUMAN; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0344043698     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199200071-00007     Document Type: Article

References (32)

1. Clozapine-pharmacokinetic investigations and biochemical effects in man
2. Clozapine-induced agranulocytosis: a situation report up to August 1976
3. T-lymphocyte-me-diated granulocyte failure
4. Clozapine: a novel antipsychotic agent
5. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection
6. Mianserin and agranulocytosis in New Zealand
7. Clozapine: an atypical antipsychotic agent
8. In vitro effect of lithium on carbamazepine-induced inhibition of murine and human bone marrow-derived granulocyte-macrophage, erythroid, and megakaryocyte progenitor stem cells
9. Polypharmacy in fatal clozapine-associated agranulocytosis
10. In vitro generation of cytotoxic lymphocytes during noramidopyrine-induced agranulocytosis
11. Dose-related plasma levels of clozapine
12. Agranulocytosis during treatment with clozapine
13. Aplastic anemia associated with lithium
14. Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol
15. The use of in vitro techniques to study drug-induced pancytopenia
16. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects
17. Leponex-associated granulocytopenia: a review of the situation
18. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin’s lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial
19. Clozapine: guidelines for clinical management
20. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
21. Ibuprofen-associated pure white-cell aplasia
22. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia
23. Penicillin G degradation products inhibit in vitro granulopoiesis
24. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients
25. Studies on agranulocytosis: a biochemical defect in chlorpromazine sensitive marrow cells
26. Immune and toxic mechanisms in drug-induced agranulocytosis
27. Aprindine-induced agranulocytosis. Evidence for immunology mechanism
28. Inhibition of fibroblast proliferation by myelotoxic drugs
29. Clozapine plasma levels and convulsions
30. The sensitivity of human bone marrow granulocyte/monocyte precursor cells to phenylbutazone, oxyphenbutazone and gamma-hydroxyphenylbutazone in vitro, with observations on the bone marrow colony formation in phenylbutazone-induced granulocytopenia
31. Comparative toxicity of chloramphenicol and thiamphenicol with particular reference to aplastic anemia